Drug intelligence / Profile preview

Artuvetrin

Development stage: Unknown
Lead developer: Nextmune
Administration: Subcutaneous

Overview

Artuvetrin is a **patient-specific veterinary allergen immunotherapy** developed by Nextmune for companion animals, especially dogs, using individualized allergen extracts selected after allergy testing. It is formulated as an aqueous alum-precipitated allergen-specific immunotherapy administered by **subcutaneous injection** in escalating doses followed by maintenance dosing, with the goal of inducing immune tolerance and reducing hypersensitivity to environmental allergens that drive **atopic dermatitis and other environmental allergies**. The product is described as licensed in Europe for dogs and is also used in cats and horses as a tailored biologic immunotherapy product.

Brand names: Artuvetrin
Other names: Artuvetrin Therapy

Beyond the preview

Go deeper on Artuvetrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artuvetrin.

Explore the full profile